Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-136751
Filing Date
2018-04-27
Accepted
2018-04-27 08:20:03
Documents
7
Period of Report
2018-06-05
Effectiveness Date
2018-04-27

Document Format Files

Seq Description Document Type Size
1 DEF14A d494847ddef14a.htm DEF 14A 402909
2 GRAPHIC g494847g02l56.jpg GRAPHIC 33906
3 GRAPHIC g494847g05k11.jpg GRAPHIC 28080
4 GRAPHIC g494847g25f08.jpg GRAPHIC 34520
5 GRAPHIC g494847pc1a.jpg GRAPHIC 15450
6 GRAPHIC g494847pc2a.jpg GRAPHIC 14350
7 GRAPHIC g494847pc2b.jpg GRAPHIC 6139
  Complete submission text file 0001193125-18-136751.txt   576217
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38266 | Film No.: 18781089
SIC: 2834 Pharmaceutical Preparations